CUBE vs RIGL · P/E 25, rev $1.07B vs P/E 9.1, rev $179.3M
CubeSmart (CUBE) versus Rigel Pharmaceuticals Inc (RIGL) — a side-by-side from cached financials, not a winner call.
CubeSmart (CUBE) is a reit - industrial company listed on US.
Rigel Pharmaceuticals Inc (RIGL) is a biotechnology company listed on US.
Latest reported CUBE revenue for 2024-12-31 was $1.07B. Net income was $391.9M. Revenue was up 1.5% from 2023-12-31 to 2024-12-31. CUBE currently screens at market cap $9.69B and trailing P/E 25.0.
Latest reported RIGL revenue for 2024-12-31 was $179.3M. Net income was $17.5M. Revenue was up 53.4% from 2023-12-31 to 2024-12-31. RIGL currently screens at market cap $338.3M and trailing P/E 9.1.
CUBE currently screens at market cap $9.69B and trailing P/E 25.0. RIGL currently screens at market cap $338.3M and trailing P/E 9.1.
Not investment advice. Open the CUBE and RIGL stock pages for the full models.
Not investment advice.